Expected Moves

Investors expect further clarity on the ongoing litigation and intellectual property disputes with Natera over transplant cell-free DNA testing. A favorable ruling, settlement terms, or de-escalation that limits downside risk to CareDx’s test portfolio could support a move toward $47.00 from $43.71. Conversely, adverse developments or prolonged uncertainty could push the stock toward $47.00 as the market discounts potential revenue and margin erosion.

CareDx reports Q3 2026 results and updates full-year 2026 guidance. After a sharp ramp in revenue to $131.9M and EPS of $2.15 in Q2, but with the share price already well above the $42 analyst consensus, the market will focus on the sustainability of transplant testing volume growth, margin quality, and any color on reimbursement or legal overhangs. A clean beat-and-raise print with stable gross margins could support a move to $39.5 from a $34.00 base, while any miss, soft guidance, or commentary suggesting normalization of recent strength could see shares pull back toward $39.50.

With a strong cash balance but elevated growth investments, investors will monitor the risk of a follow-on equity or convertible offering if market conditions remain favorable and the share price holds above prior ranges. A disciplined decision to delay or structure any financing with minimal dilution could support the stock toward $35.50. An unexpectedly large or discounted raise could drive shares toward $35.50 as existing holders price in dilution and question capital allocation.

CareDx is expected to report Q4 2026 results and issue initial 2027 guidance. With revenue growth running above 50% YoY but earnings quality and reimbursement visibility still in focus, investors will look for evidence that the company can sustain double-digit growth while generating consistent free cash flow. If management delivers a credible 2027 growth and margin framework with no new reimbursement or legal surprises, shares could rebound toward $33.00. A guidance reset, slowing transplant testing volumes, or renewed margin pressure would likely push the stock down toward $33.00 as the market re-rates the long-term growth story.

CareDx’s Q1 2027 report will be the first real test of whether the 2027 guidance framework is credible, with investors focusing on transplant test order trends, gross margin mix, and operating leverage. A print that tracks or modestly exceeds expectations with reaffirmed guidance could help the stock stabilize and drift toward $26.50. A miss on volumes or a guidance cut this early in the year would likely erode confidence and drive shares down toward $26.50.

Mid-2027 results will show whether CareDx’s transplant testing franchise is regaining momentum and whether earlier reimbursement and legal risks have stabilized. If volumes track to plan and management can highlight durable free cash flow generation, shares could grind up toward $20.50. If growth decelerates further or new payor pressure emerges, the stock could slip toward $20.50 as investors rotate to higher-visibility diagnostics names.